Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 6/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.36 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23441518 | 1.00 | LTC4S (0.36) | LTC4SFFAR1TRPC6FFAR4SCN9A | |
| SCHEMBL23441541 | 1.00 | LTC4S (0.36) | LTC4SFFAR1TRPC6FFAR4SCN9A | |
| SCHEMBL31305496 | 1.00 | LTC4S (0.36) | LTC4SFFAR1TRPC6FFAR4SCN9A | |
| SCHEMBL30406011 | 1.00 | LTC4S (0.36) | LTC4SFFAR1TRPC6FFAR4SCN9A | |
| SCHEMBL23441505 | 1.00 | LTC4S (0.36) | LTC4SFFAR1TRPC6FFAR4SCN9A | |
| SCHEMBL23441519 | 1.00 | LTC4S (0.36) | LTC4SFFAR1TRPC6FFAR4SCN9A | |
| SCHEMBL23441517 | 1.00 | LTC4S (0.36) | LTC4SFFAR1TRPC6FFAR4SCN9A | |
| SCHEMBL29318117 | 0.90 | HTR2C (0.37) | LTC4SFFAR1FFAR4HTR2CCYP11B1 | |
| SCHEMBL29318119 | 0.90 | HTR2C (0.37) | LTC4SFFAR1FFAR4HTR2CCYP11B1 | |
| SCHEMBL27194558 | 0.87 | KDM1A (0.36) | LTC4STRPC6FFAR4SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219452-B1 | NOVEL 3,5-DISUBSTITUTED PYRIDINE AND 3,5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2025-01-01 | — | — | EP | claimed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | claimed |
| US-11958812-B2 | 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-04-16 | — | — | US | claimed |
| EP-4219452-A1 | NOVEL 3,5-DISUBSTITUTED PYRIDINE AND 3,5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-08-02 | — | — | EP | claimed |
| EP-3831812-B1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2023-05-10 | — | — | EP | claimed |
| US-20220298118-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-09-22 | — | — | US | claimed |
| EP-3831812-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-06-09 | — | — | EP | claimed |
| CN-112469699-A | Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and medical application thereof | 田边三菱制药株式会社 | 2021-03-09 | — | — | CN | claimed |
| US-12404247-B2 | 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-09-02 | — | — | US | disclosed |
| EP-4527464-A2 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-03-26 | — | — | EP | disclosed |
| EP-4219452-B1 | NOVEL 3,5-DISUBSTITUTED PYRIDINE AND 3,5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2025-01-01 | — | — | EP | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-11958812-B2 | 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-112469699-B | Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and medical application thereof | 田边三菱制药株式会社 | 2024-02-23 | — | — | CN | disclosed |
| EP-4219452-A1 | NOVEL 3,5-DISUBSTITUTED PYRIDINE AND 3,5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-3831812-B1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20220298118-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-09-22 | — | — | US | disclosed |
| EP-3831812-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-06-09 | — | — | EP | disclosed |
| CN-112469699-A | Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and medical application thereof | 田边三菱制药株式会社 | 2021-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404247-B2 | 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | ENPP2, PGA5, PLPBP | LTC4S 309/4885FFAR1 1889/4885TRPC6 828/4885 |
| US-20220298118-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ATXN2, ATXN10, ATXN2L | LTC4S 579/4885FFAR1 3355/4885TRPC6 2317/4885 |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | LTC4S 218/4885FFAR1 1458/4885TRPC6 537/4885 |
| US-11958812-B2 | 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | ATXN2, ATXN10, ARSA | LTC4S 442/4885FFAR1 3341/4885TRPC6 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.